Drug Profile
ER 022604
Latest Information Update: 05 Jul 2007
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Neuroprotectants
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Peripheral nervous system diseases
Most Recent Events
- 27 Apr 2004 Preclinical trials in Amyotrophic lateral sclerosis in Japan (unspecified route)
- 27 Apr 2004 Preclinical trials in Spinal cord injuries in Japan (unspecified route)